Filtered By:
Vaccination: Pneomococcal Vaccine

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 303 results found since Jan 2013.

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that ...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. These data ...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Care of rheumatology patients during the lockdown in early 2020 : Telemedicine, delegation, patient satisfaction and vaccination behavior
CONCLUSION: Telemedical care within the framework of a telephone consultation is well-suited for selected patients. With respect to patient satisfaction the delegation of a telemedical consultation to an RFA is possible. There is a need for improvement with respect to the vaccination behavior.PMID:33974131 | PMC:PMC8111653 | DOI:10.1007/s00393-021-01005-3
Source: Zeitschrift fur Rheumatologie - May 11, 2021 Category: Rheumatology Authors: Thea Thiele Sonja Beider Henrik K ühl Gudrun Mielke Anna Holz Stefanie Hirsch Torsten Witte Kirsten Hoeper Anne Cossmann Christine Happle Alexandra Jablonka Diana Ernst Source Type: research

Sickle cell disease in newborns and children: What families should know and do
If you’ve learned that your newborn or young child has sickle cell disease, you — and other family members and friends — may have many questions. These days, most cases of sickle cell disease in the US are diagnosed through newborn screening. It’s important to make the diagnosis early, so that babies can be started on penicillin (or another antibiotic) to prevent infection. Getting connected early to a pediatrician for primary care — and to specialists in blood disorders who can work closely with the child as they grow, and with their families — can help prevent complications of the disease. The basics Hemoglob...
Source: Harvard Health Blog - May 6, 2021 Category: Consumer Health News Authors: Claire McCarthy, MD Tags: Children's Health Genes Health care disparities Parenting Source Type: blogs

Adverse events following yellow fever vaccination in immunocompromised persons
Rev Inst Med Trop Sao Paulo. 2021 Mar 1;63:e13. doi: 10.1590/S1678-9946202163013. eCollection 2021.ABSTRACTThis observational retrospective study conducted during an yellow fever (YF) outbreak in Sao Paulo, Brazil, in 2017-2018, describes adverse events (AE) following YF vaccination of immunocompromised persons. Risks and benefits of vaccination were individually evaluated by physicians. AE were assessed by phone call or electronic mail, 14 to 90 days after vaccination. Three hundred and eighty one immunocompromised persons received a full-dose of YF vaccine. Their age ranged from 1.4 to 89.3 years (median 50.8 years); 53%...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - March 3, 2021 Category: Tropical Medicine Authors: Amanda Nazareth Lara Karina Takesaki Miyaji Karim Yaqub Ibrahim Marta Heloisa Lopes Ana Marli Christovam Sartori Source Type: research